.jpg)
Lilly's weight-loss drug cuts diabetes risk by 94% in three-year trial, company says
Eli Lilly’s weight loss drug cut the risk of developing Type 2 diabetes by 94% in prediabetic adults who were overweight or obese after three years of weekly injections, the company disclosed in a statement on Tuesday.
Eli Lilly’s weight loss drug cut the risk of developing Type 2 diabetes by 94% in prediabetic adults who were overweight or obese after three years of weekly injections, the company disclosed in a statement on Tuesday.
What's Your Reaction?
.gif)